Alx Oncology Holdings Inc (ALXO) Institutional Ownership

Ownership Summary

Alx Oncology Holdings Inc (NASDAQ:ALXO) has 55 institutional investors with active 13F positions as of December 2025.

• Collectively, these holders controlled 54.4% of Alx Oncology Holdings's outstanding shares in December 2025, down from 57.7% in September 2025.
• Their total shares held in ALXO decreased -1.49% quarter over quarter, and separately, investors owning Alx Oncology Holdings decreased 35.29% from a year ago.
• During the quarter, 25 of these 55 funds increased positions in ALXO, 16 reduced exposure, and 14 held steady.
• The aggregate institutional position in Alx Oncology Holdings amounted to 29.15Mn shares as of December 2025, down by 442.45K shares quarter on quarter, and down 14.68Mn shares year over year.
• As of December 31, 2025, venBio Partners LLC held the largest stake in Alx Oncology Holdings with 9.7Mn shares, accounting for 18.1% of total shares outstanding.
• The biggest buyers of Alx Oncology Holdings for the quarter ending December 2025 included UBS Group AG (693.42K), DRIEHAUS CAPITAL MANAGEMENT LLC (627.1K), MILLENNIUM MANAGEMENT LLC (581.76K), RENAISSANCE TECHNOLOGIES LLC (258.6K), ACADIAN ASSET MANAGEMENT LLC (153.45K).
• Leading sellers of Alx Oncology Holdings shares for the quarter ending December 2025 were Almitas Capital LLC (2.54Mn), Bank Of America Corp /De/ (529.81K), Jpmorgan Chase & Co (123.7K), Redmile Group, LLC (68.26K), MARSHALL WACE, LLP (13.21K).
• Business Quant data shows the 10 biggest positions in Alx Oncology Holdings as of December 2025 are held by venBio Partners LLC (9.7Mn), Redmile Group, LLC (3.26Mn), MILLENNIUM MANAGEMENT LLC (3.2Mn), Almitas Capital LLC (2.54Mn), VANGUARD GROUP INC (1.63Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (1.42Mn), ACADIAN ASSET MANAGEMENT LLC (1.37Mn), UBS Group AG (865.99K), TWO SIGMA ADVISERS, LP (710.4K), TWO SIGMA INVESTMENTS, LP (640.21K).